Presented in part at the 31st Annual Meeting of the Japanese Society for Apheresis held 4–6 November 2010 in Chiba, Japan.
1744-9987/asset/TAP_left.gif?v=1&s=7d875b016e0b3276e36e8e680437a2e08aa2af1d)
1744-9987/asset/TAP_right.gif?v=1&s=cfcdd17dd618cfdddf584eaf319e437572c8768b)
You have free access to this content
Complete Early Virological Response Was Highly Achieved by Double Filtration Plasmapheresis Plus IFN-Beta Induction Therapy for HCV-1b Patients With Relapse or No Response After Previous IFN Therapy
Article first published online: 24 AUG 2011
DOI: 10.1111/j.1744-9987.2011.00965.x
© 2011 The Authors. Therapeutic Apheresis and Dialysis © 2011 International Society for Apheresis
Additional Information
How to Cite
Ishikawa, T., Higuchi, K., Kubota, T., Seki, K.-i., Honma, T., Yoshida, T., Kamimura, T., Tasaki, K., Hirose, S. and Suzuki, Y. (2011), Complete Early Virological Response Was Highly Achieved by Double Filtration Plasmapheresis Plus IFN-Beta Induction Therapy for HCV-1b Patients With Relapse or No Response After Previous IFN Therapy. Therapeutic Apheresis and Dialysis, 15: 400–405. doi: 10.1111/j.1744-9987.2011.00965.x
Publication History
- Issue published online: 24 AUG 2011
- Article first published online: 24 AUG 2011
- Received December 2010; revised January 2011.
- Abstract
- Article
- References
- Cited By
Keywords:
- Complete early virological response;
- Double filtration plasmapheresis;
- IFN-β induction;
- Virus removal and eradication by DFPP
Abstract
The efficacy of double filtration plasmapheresis (DFPP) plus interferon (IFN)-β induction therapy was preliminarily investigated in re-treated patients with chronic genotype 1b hepatitis C and high viral load (patients with relapse or non-response to previous IFN therapies). In eight patients with chronic hepatitis C, DFPP was performed five times over 2 weeks during IFN-β therapy, and 3 MU of IFN-β was administered twice a day for 2 weeks. Combination therapies with ribavirin and pegylated IFN-α2b (PEG-IFN-α2b) or pegylated IFN-α2a (PEG-IFN-α2a) were subsequently used. After 4 weeks, hepatitis C virus (HCV)-RNA tended to be more greatly decreased with DFPP combination therapy than with previous IFN therapy (4.5 ± 2.0 log10IU/mL vs. 2.9 ± 1.2 log10IU/mL). Rates of both rapid virological response and complete early virological response were significantly higher with DFPP and IFN-β induction therapy than with previous IFN therapy. DFPP plus IFN-β induction therapy produced a great reduction of viral load during the early stage of treatment and achieved a high early virological response, suggesting that this combination therapy may be useful as a new treatment modality for chronic hepatitis C patients in difficult-to-treat states. This combination may contribute to sustained virological response (SVR). The effects of DFPP on SVR and its significance remain to be clarified.